Severe pulmonary hypertension in lung disease: phenotypes and response to treatment

被引:53
作者
Brewis, Melanie J. [1 ]
Church, Alistair C. [1 ]
Johnson, Martin K. [1 ]
Peacock, Andrew J. [1 ]
机构
[1] Golden Jubilee Natl Hosp, Scottish Pulm Vasc Unit, Glasgow G81 4DY, Lanark, Scotland
关键词
TERM OXYGEN-THERAPY; ARTERIAL-HYPERTENSION; NATRIURETIC PEPTIDE; NT-PROBNP; ACUTE EXACERBATIONS; EMPHYSEMA SYNDROME; COPD PATIENTS; GAS-EXCHANGE; DYSFUNCTION; FIBROSIS;
D O I
10.1183/13993003.02307-2014
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Pulmonary hypertension (PH) due to lung disease (World Health Organization (WHO) group 3) is common, but severe PH, arbitrarily defined as mean pulmonary artery pressure >= 35 mmHg is reported in only a small proportion. Whether these should be treated as patients in WHO group 1 (i.e. pulmonary arterial hypertension) with PH-targeted therapies is unknown. We compared the phenotypic characteristics and outcomes of 118 incident patients with severe PH and lung disease with 74 idiopathic pulmonary arterial hypertension (IPAH) patients, all treated with pulmonary vasodilators. Lung disease patients were older, more hypoxaemic, and had lower gas transfer, worse New York Heart Association functional class and lower 6-min walking distance (6MWD) than IPAH patients. Poorer survival in those with lung disease was driven by the interstitial lung disease (ILD) cohort. In contrast to IPAH, where significant improvements in 6MWD and N-terminal pro-brain natruiretic peptide (NT-proBNP) occurred, PH therapy in severe PH lung disease did not lead to improvement in 6MWD or functional class, but neither was deterioration seen. NT-proBNP decreased from 2200 to 1596 pg.mL(-1) (p=0.015). Response varied by lung disease phenotype, with poorer outcomes in patients with ILD and emphysema with preserved forced expiratory volume in 1 s. Further study is required to investigate whether vasodilator therapy may delay disease progression in severe PH with lung disease.
引用
收藏
页码:1378 / 1389
页数:12
相关论文
共 50 条
[41]   Pulmonary hypertension and chronic lung disease: where are we headed? [J].
Elia, Davide ;
Caminati, Antonella ;
Zompatori, Maurizio ;
Cassandro, Roberto ;
Lonati, Chiara ;
Luisi, Francesca ;
Pelosi, Giuseppe ;
Provencher, Steeve ;
Harari, Sergio .
EUROPEAN RESPIRATORY REVIEW, 2019, 28 (153)
[42]   Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia [J].
Heresi, Gustavo A. ;
Platt, David M. ;
Wang, Wenyi ;
Divers, Christine H. ;
Joish, Vijay N. ;
Teal, Simon A. ;
Yu, Justin S. .
BMC PULMONARY MEDICINE, 2017, 17
[43]   Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial [J].
Hoeper, Marius M. ;
Halank, Michael ;
Wilkens, Heinrike ;
Guenther, Andreas ;
Weimann, Gerrit ;
Gebert, Irmingard ;
Leuchte, Hanno H. ;
Behr, Juergen .
EUROPEAN RESPIRATORY JOURNAL, 2013, 41 (04) :853-860
[44]   Pathogenesis, clinical features, and phenotypes of pulmonary hypertension associated with interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative - Group 3 Pulmonary Hypertension [J].
Piccari, Lucilla ;
Allwood, Brian ;
Antoniou, Katerina ;
Chung, Jonathan H. ;
Hassoun, Paul M. ;
Nikkho, Sylvia M. ;
Saggar, Rajan ;
Shlobin, Oksana A. ;
Vitulo, Patrizio ;
Nathan, Steven D. ;
Wort, Stephen John .
PULMONARY CIRCULATION, 2023, 13 (02)
[45]   Impact of targeted pulmonary arterial hypertension therapies in severe pulmonary hypertension in chronic lung diseases [J].
Naud, Romain ;
Bermudez, Julien ;
Resseguier, Noemie ;
Nieves, Ana ;
Coltey, Berengere ;
Dufeu, Nadine ;
Gautier, Clarisse ;
Trigui, Youssef ;
Laine, Marc ;
Coiffard, Benjamin ;
Reynaud-Gaubert, Martine .
ERJ OPEN RESEARCH, 2023, 9 (04)
[46]   Pulmonary hypertension in systemic sclerosis: different phenotypes [J].
Launay, David ;
Sobanski, Vincent ;
Hachulla, Eric ;
Humbert, Marc .
EUROPEAN RESPIRATORY REVIEW, 2017, 26 (145)
[47]   Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease [J].
Gillmeyer, Kari R. ;
Miller, Donald R. ;
Glickman, Mark E. ;
Qian, Shirley X. ;
Klings, Elizabeth S. ;
Maron, Bradley A. ;
Hanlon, Joseph T. ;
Rinne, Seppo T. ;
Wiener, Renda S. .
PULMONARY CIRCULATION, 2021, 11 (01)
[48]   Echocardiography Nomogram for Predicting Survival among Chronic Lung Disease Patients with Severe Pulmonary Hypertension [J].
Jiang, Rong ;
Wang, Lan ;
Zhao, Qin-Hua ;
Wu, Cheng ;
Yuan, Ping ;
Wang, Shang ;
Zhang, Rui ;
Gong, Su-Gang ;
Wu, Wen-Hui ;
He, Jing ;
Qiu, Hong-Ling ;
Luo, Ci-Jun ;
Liu, Jin-Ming ;
Jing, Zhi-Cheng .
JOURNAL OF CLINICAL MEDICINE, 2022, 11 (06)
[49]   Pulmonary hypertension due to interstitial lung disease [J].
King, Christopher S. ;
Nathan, Steven D. .
CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (05) :459-467
[50]   Lung Disease-Related Pulmonary Hypertension [J].
Ahmad, Kareem ;
Khangoora, Vikramjit ;
Nathan, Steven D. .
CARDIOLOGY CLINICS, 2022, 40 (01) :77-88